Small molecule targeting of the p38/Mk2 stress signaling pathways to improve cancer treatment

Although a long-term goal of cancer therapy always has been the development of agents that selectively destroy cancer cells, more recent trends have been to seek secondary agents that sensitize cancer cells to existing treatment regimens.